当前位置: 首页 > 详情页

CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Affiliated Beijing Anzhen Hosp, Inst Beijing Heart Lung & Blood Vessel Dis, Dept Obstet & Gynecol, Beijing 100029, Peoples R China; [2]Chinese Acad Sci, Chinese Acad Sci Univ Tokyo Joint Lab Struct Viro, Inst Biophys, Prot & Peptide Pharmaceut Lab, Beijing 100101, Peoples R China; [3]Zhengzhou Univ, Affiliated Hosp 5, Dept Obstet & Gynecol, Zhengzhou 450000, Peoples R China; [4]Chinese Acad Sci, Chinese Acad Sci Univ Tokyo Joint Lab Struct Viro, Inst Biophys, Prot & Peptide Pharmaceut Lab, 15 Datun Rd, Beijing 100101, Peoples R China
出处:
ISSN:

关键词: CD146 marker diagnostic testing anti-CD146 mAb AA4 cervical cancer endometrial cancer

摘要:
Cluster of differentiation 146 (CD146) is an endothelial cell adhesion molecule which is overexpressed in various types of malignant cancer, including ovarian cancer. However, whether CD146 is overexpressed in another two types of gynecological cancer, cervical cancer and endometrial cancer, remains unclear. In the present study, we showed that CD146 expression levels were higher in cells from cervical cancer and endometrial cancer compared with their corresponding normal tissues, using anti-CD146 mouse antibody AA4 (mAb AA4) and that mAb AA4 exhibited a high performance for specificity, sensitivity and positive predictive value in the detection of these two types of cancer. CD146 expression was positively and significantly correlated with the pathological subtype of cervical cancer and with the histological grade and depth of myometrial invasion in endometrial cancer. In addition, we confirmed that CD146 is present in the majority of blood vessels in cervical and endometrial cancer, suggesting that CD146 may be actively implicated in the metastasis of cervical and endometrial cancer via the vascular system. Thus, this study provides insights for further development of CD146 mAb in the detection of gynecological malignant cancer types and implies that a combined treatment strategy of anti-CD146 immunotherapy with other traditional chemo-or radiotherapy treatments may be a promising approach against cervical and endometrial cancer.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2011]版:
Q4 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [1]Capital Med Univ, Affiliated Beijing Anzhen Hosp, Inst Beijing Heart Lung & Blood Vessel Dis, Dept Obstet & Gynecol, Beijing 100029, Peoples R China;
通讯作者:
通讯机构: [2]Chinese Acad Sci, Chinese Acad Sci Univ Tokyo Joint Lab Struct Viro, Inst Biophys, Prot & Peptide Pharmaceut Lab, Beijing 100101, Peoples R China; [4]Chinese Acad Sci, Chinese Acad Sci Univ Tokyo Joint Lab Struct Viro, Inst Biophys, Prot & Peptide Pharmaceut Lab, 15 Datun Rd, Beijing 100101, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16991 今日访问量:0 总访问量:905 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院